ZAXOPAM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZAXOPAM (ZAXOPAM).
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
| Metabolism | Hepatic via CYP3A4 and CYP2C19 isoenzymes; major metabolites include active metabolites (e.g., desalkylzaxopam). |
| Excretion | Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%. |
| Half-life | Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients. |
| Protein binding | 95-98% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating moderate distribution into total body water and tissues. |
| Bioavailability | Oral: 80-90% due to minimal first-pass metabolism; intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 1-3 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 2-4 hours. Extended duration possible with hepatic impairment. |
| Molecular Weight | 300 |
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
| Dosage form | CAPSULE |
| Renal impairment | eGFR 30-59 mL/min: administer 50% of usual dose; eGFR <30 mL/min: not recommended. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: initiate at 50% of usual dose; Child-Pugh Class C: contraindicated. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | Initiate at 5 mg orally twice daily; increase cautiously with careful monitoring for adverse effects. |
| 1st trimester | Avoid use; benzodiazepines are associated with increased risk of congenital malformations, particularly oral clefts, in first trimester exposure. |
| 2nd trimester | Use only if clearly needed; potential risks include poor fetal growth and neurodevelopmental effects. Monitor for withdrawal in neonate. |
| 3rd trimester | Avoid near term; risk of neonatal respiratory depression, sedation, floppy infant syndrome, and withdrawal symptoms. Use only if benefit outweighs risks. |
Clinical note
Comprehensive clinical and safety monograph for ZAXOPAM (ZAXOPAM).
| Placental transfer | Benzodiazepines cross the placenta readily, with cord blood levels typically equal to maternal serum levels. Zaxopam shows significant transfer based on lipophilicity and molecular weight. |
| Breastfeeding | Zaxopam is excreted into breast milk; infants may accumulate due to long half-life. Monitor for sedation, poor feeding, and weight loss. Avoid if possible; if used, lowest effective dose and limit duration. |
■ FDA Black Box Warning
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant use for patients without alternative treatment options.
| Serious Effects |
Known hypersensitivity to benzodiazepinesSevere hepatic impairmentNarrow-angle glaucomaMyasthenia gravisSevere respiratory insufficiencySleep apnea syndrome
| Precautions | Risk of dependence and withdrawal reactions; tolerance may develop; caution in hepatic impairment; risk of anterograde amnesia; monitor for respiratory depression, especially in elderly or debilitated patients. |
| Food/Dietary | Grapefruit and grapefruit juice inhibit CYP3A4 metabolism, increasing zaxopam exposure; avoid concurrent intake. High-fat meals may delay absorption but do not alter overall exposure. Limit caffeine intake as it may reduce anxiolytic effect. |
Loading safety data…
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | ZAXOPAM is a benzodiazepine. First trimester: associated with increased risk of congenital malformations (cleft palate, inguinal hernia, cardiac defects) based on observational studies; relative risk approximately 2.0. Second and third trimesters: exposure may cause fetal central nervous system depression, hypotonia, withdrawal symptoms (floppy infant syndrome), and respiratory depression at delivery. |
| Fetal Monitoring | Monitor maternal vital signs, sedation level, and respiratory rate. Fetal monitoring: nonstress test and biophysical profile in third trimester; assess fetal growth with serial ultrasound. At delivery, monitor neonate for respiratory depression, hypotonia, and withdrawal symptoms (irritability, tremors). Long-term neurodevelopmental follow-up recommended. |
| Fertility Effects | ZAXOPAM may cause menstrual irregularities, anovulation, or decreased libido in females. In males, it may reduce sperm motility and concentration. These effects are generally reversible upon discontinuation. Animal studies show no direct impairment of fertility at clinically relevant doses. |
| Clinical Pearls | Zaxopam (active ingredient: zaxopam) is a benzodiazepine-class anxiolytic with rapid onset of action (15-30 min oral). Avoid IV administration due to risk of thrombophlebitis. Caution in elderly: reduce starting dose by 50% to minimize sedation and fall risk. Monitor for paradoxical disinhibition in pediatric and psychiatric populations. |
| Patient Advice | Avoid alcohol and other CNS depressants. · Do not drive or operate machinery until you know how this drug affects you. · Take exactly as prescribed; do not increase dose or duration. · Do not stop abruptly; taper under medical supervision to avoid withdrawal. · Potential for dependence and abuse; store securely. |